Pulsecare Medical Gains NMPA Approval for World’s First Nanosecond PFA System

Pulsecare Medical has received marketing authorization from China’s National Medical Products Administration (NMPA) for its NxPFA™ nanosecond pulsed field ablation system, the first device of its kind globally to use nanosecond-scale pulses for treating atrial fibrillation (AF).

Pulsed field ablation is increasingly viewed as a next-generation alternative to conventional ablation because it selectively targets heart muscle while sparing surrounding tissues. 

Earlier platforms that relied on microsecond pulses struggled with issues such as strong involuntary muscle contractions, the need for general anesthesia, and complications including blood cell damage and gas formation. These drawbacks limited their routine use.

The newly approved NxPFA™ platform integrates the MaviPulse™ console with the InteShot™ basket catheter, allowing precise ablation with far less neuromuscular stimulation. 

This enables treatment to be performed under conscious sedation, improving patient comfort and reducing anesthesia-related risks. The system also lowers the chance of hemolysis and gas-related complications, which in turn decreases the risk of kidney injury and stroke.

Evidence for the technology came from the SCENA-AF multicenter registration trial, which enrolled 166 patients with paroxysmal AF. 

The study reported complete pulmonary vein isolation in every case, an 88.27 percent treatment success rate at one year, and no serious adverse events linked to the device. More than 92 percent of patients were treated successfully without general anesthesia, and most tolerated the procedure well.

With this regulatory clearance, NxPFA™ is now the only commercially available system capable of delivering single-shot pulmonary vein isolation using conscious sedation. 

Pulsecare Medical sees this as an important milestone for arrhythmia treatment, giving clinicians a more advanced therapeutic option and offering patients a safer, more comfortable procedure.